- Home
- MBIO
MBIO
Mustang Bio Inc.
as 05-20-2024 3:33pm EST
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | WORCESTER |
| Market Cap: | 3.3M | IPO Year: | N/A |
| Target Price: | $12.00 | AVG Volume (30 days): | 261.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.40 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.22 - $8.17 | Next Earning Date: | 05-15-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Share on Social Networks:
Latest Mustang Bio Inc. News
MBIO Breaking Stock News: Dive into MBIO Ticker-Specific Updates for Smart Investing
GlobeNewswire
18 days ago
Mustang Bio Announces Closing of $4 Million Public Offering
MT Newswires
20 days ago
Mustang Bio Prices Public Offering of 16.9 Million Shares, Accompanying Warrants
GlobeNewswire
21 days ago
Mustang Bio Announces Pricing of $4 Million Public Offering
GlobeNewswire
2 months ago
Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases
GlobeNewswire
2 months ago
Mustang Bio Reports Full-Year 2023 Financial Results and Recent Corporate Highlights
GlobeNewswire
2 months ago
Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade Glioma
GlobeNewswire
4 months ago
InterCure Signs Definitive Agreement to Acquire Leon Cannabis Pharmacy Chain
GlobeNewswire
4 months ago